Search Results 641-650 of 18599 for alopecia

1. A Phase 1B Dose-escalation Study Of TRC105 In Combination With Pazopanib In Patients With Advanced Soft Tissue Sarcoma - Mayo Clinic

   Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline (except alopecia or neuropathy); Adequate ...

2. A Open Label Study Of The Efficacy And Safety Of PD0332991 A Selective Inhibitor Of The Cyclin Dependent Kinases 4 And 6 In Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency And Low P16 Expression - Mayo Clinic

   Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE v.3.0 Grade ≤ 1 and to baseline laboratory values as defined in the ...

3. Birinapant With 5-azacitidine In MDS Subjects Who Are Naïve, Have Relapsed Or Are Refractory To 5-azacitidine Therapy - Mayo Clinic

   ... alopecia) due to therapy administered prior to the initiation of study drug dosing. Nursing or pregnant women. Known allergy to any of the formulation ...

4. Study Of Pazopanib In The Treatment Of Osteosarcoma Metastatic To The Lung - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. An untreated tumor growth ...

5. Publications - Elizabeth J. Cathcart-Rake, M.D. - Mayo Clinic

   ... alopecia in breast cancer patients. Support Care Cancer. 2023 Nov 22; 31 (12):717. View PubMed; Cathcart-Rake EJ, Tevaarwerk AJ, Haddad TC, D'Andre SD, Ruddy ...

6. Study Of Pazopanib In The Treatment Of Surgically Unresectable Or Metastatic Chondrosarcoma - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. Known immediate or delayed ...

7. Study Of DCC-3014 In Patients With Advanced Tumors And Tenosynovial Giant Cell Tumor - Mayo Clinic

   Unresolved toxicity (> Grade 1 or baseline) from previous anticancer therapy, excluding alopecia. Known active CNS metastases. History or presence of ...

8. Testing The Use Of The Combination Of Selumetinib And Olaparib Or Selumetinib Alone Targeted Treatment For RAS Pathway Mutant Recurrent Or Persistent Ovarian And Endometrial Cancers, A ComboMATCH Treatment Trial - Mayo Clinic

   ... alopecia - Patients with uncontrolled intercurrent illness - Patients with >= grade 2 neuropathy within 14 days of registration - Patients with severe ...

9. Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer - Mayo Clinic

   ... alopecia, are excluded. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to axatilimab or olaparib ...

10. Study Of Azacitidine With Or Without Birinapant In Subjects With MDS Or CMMoL - Mayo Clinic

    ... alopecia) due to therapy administered prior to the initiation of study drug dosing. Nursing or pregnant. Known allergy or hypersensitivity to any of the ...